Dianthus Therapeutics, Inc. (DNTH) Cash Flow Statement
Dianthus Therapeutics, Inc. (DNTH) generated -$155.4M of operating cash flow over the twelve months to 2026-06-30, spent $334000 on capital expenditure and had free cash flow of -$155.7M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
DNTHDianthus Therapeutics, Inc.Follow DNTH — free
—
Price chart with a free account
- Market cap
- 4.3B
- P/E TTM
- —
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Operating cash flow | -0.04 | -0.08 | -0.13 | -0.16 | |
| Capital expenditure | 0.00 | 0.00 | 0.00 | -0.00 | |
| Free cash flow | -0.04 | -0.08 | -0.13 | -0.16 | |
| Stock-based compensation | 0.00 | 0.01 | 0.02 | — |
USD billions · SEC XBRL
Dianthus Therapeutics, Inc. — questions
- What is Dianthus Therapeutics, Inc.'s operating cash flow?
- -$155.4M over the twelve months to 2026-06-30.
- How much does Dianthus Therapeutics, Inc. spend on capital expenditure?
- $334000 over the twelve months to 2026-06-30.
- What is Dianthus Therapeutics, Inc.'s free cash flow?
- -$155.7M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Dianthus Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.